Countries China

Novo Holdings Makes Strategic Investment in China’s Wound Care CDMO ForYou Medical

Novo Holdings, a leading global healthcare and life sciences investor, announced a strategic minority investment in Huizhou ForYou Medical Devices Co., Ltd...

 September 14, 2026 | News

TenNor’s TNP-2092 Shows 100% Treatment Success in Early, Acute PJI Phase IIa Trial

TenNor Therapeutics, a near-commercial-stage biotechnology company, announced positive topline results from a Phase IIa proof-of-concept (POC) trial of rif...

 September 14, 2026 | News

Exegenesis Bio, Modalis Partner to Advance CRISPR-Based DMD Therapy MDL-201

Exegenesis Bio and Modalis Therapeutics Corporation (TOKYO: 4883; "Modalis")  announced that they have signed a research collaboration and license agr...

 September 14, 2026 | News

Transcenta Licenses HiCB Bioprocessing Technology to WuXi Biologics in Strategic Collaboration

Transcenta Therapeutics (HKEX: 06628), a global clinical-stage biopharmaceutical company with fully integrated capabilities in discovery, R&D and proce...

 September 11, 2026 | News

Gan&Lee Doses First Participant in Phase I Trial of Once-Weekly Oral GLP-1 Candidate GZC8072

Gan&Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan&Lee) announced that the first participant has been dosed in a First-In-Human (FIH...

 September 11, 2026 | News

BGI Genomics Unveils Digital Life Twin Framework for Predictive Health Management

Commemorating BGI Group's 27th anniversary, BGI Genomics introduced its Digital Life Twin framework alongside an advanced multi-omics diagnostic portfolio ...

 September 11, 2026 | News

Solstice Oncology Launches with $225M Series A to Advance Harbour BioMed’s Porustobart

Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning...

 September 11, 2026 | News

Kelun-Biotech’s Twice-Yearly Asthma Candidate SKB378 Advances into Phase III

The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. ...

 September 10, 2026 | News

Alebund Secures US FDA IND Clearance for First-in-Class IgA Nephropathy Therapy AP308

Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, announced that it has recen...

 September 10, 2026 | News

Harbour BioMed’s HBM9378 Shows Sustained Asthma Control with Twice-Yearly Dosing Potential

The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. ...

 September 10, 2026 | News

Accro, Fosun Pharma Secure China Nod for Phase II/III Trial of AC-201 in Vitiligo

Accro Bioscience (Suzhou) Limited ("Accro") today announced that Shanghai Fosun Pharmaceutical Industrial Development Company Limited ("Fosun Pharma Indust...

 September 10, 2026 | News

CelluPro Becomes First Chinese Cell Culture Media Supplier to Secure EXCiPACT GMP Certification

CelluPro, a biotechnology company specializing in serum-free cell culture media and bioprocess solutions, has achieved EXCiPACT™ GMP Certif...

 September 09, 2026 | News

CorrectSequence’s Base-Editing Therapy Shows Durable Response Across Diverse β-Hemoglobinopathy Patients

Following 100% transfusion independence in Chinese TDT patients, new study confirms tBE is equally safe and effective for African SCD patients and TDT pati...

 September 09, 2026 | News

Clover Biopharmaceuticals Reports Positive Phase II Results for RSV-hMPV-PIV3 Combination Vaccines

-- Positive Phase 2 (Australia) results strengthen potential best-in-class profile of RSV+hMPV±PIV3 combination vaccines, with the potential differe...

 September 08, 2026 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close